Skip to content
HowShorted

LA JOLLA PHARMACEUTICAL CO short interest in 2019

In 2019, LA JOLLA PHARMACEUTICAL CO's disclosed short interest ran from 25.65% of shares outstanding on 15 Jan 2019 to 13.47% on 31 Dec 2019, a change of -12.18 percentage points. The year's high was 28.38% on 28 Feb 2019 and its low 12.20% on 29 Nov 2019, averaging 20.08% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.21 days on 31 Jul 2019. Full history: LA JOLLA PHARMACEUTICAL CO.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for LA JOLLA PHARMACEUTICAL CO in 2019

2019 in figures

Start of year
25.65% (15 Jan 2019)
End of year
13.47% (31 Dec 2019)
Change
-12.18 pp
High
28.38% (28 Feb 2019)
Low
12.20% (29 Nov 2019)
Average
20.08%
Highest days to cover
18.21 (31 Jul 2019)
SEC filings marked
8

Every report in 2019

LA JOLLA PHARMACEUTICAL CO short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201925.65%2.50results (8-K)
31 Jan 201927.37%8.57
15 Feb 201927.80%16.81
28 Feb 201928.38%13.86
15 Mar 201925.39%6.1510-K filed, results (8-K)
29 Mar 201921.85%8.77
15 Apr 201921.02%15.46
30 Apr 201920.74%14.00
15 May 201917.86%7.3410-Q filed, results (8-K)
31 May 201918.70%14.69
14 Jun 201922.29%1.10
28 Jun 201923.01%8.73
15 Jul 201922.66%15.71
31 Jul 201921.79%18.21
15 Aug 201920.82%15.8810-Q filed, results (8-K)
30 Aug 201919.44%15.58
13 Sep 201917.39%11.66
30 Sep 201916.45%16.83
15 Oct 201913.93%14.38
31 Oct 201914.55%12.41
15 Nov 201914.45%14.9710-Q filed
29 Nov 201912.20%1.73
13 Dec 201914.68%2.99
31 Dec 201913.47%3.02

See also: LA JOLLA PHARMACEUTICAL CO's full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.